Loading…
Viking Therapeutics, Inc. is projected to rise to $42.01 by 2027, a +33% move from its current price of $31.66. VKTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $30.91 | $31.68 | $32.46 | +0.05% |
| May 30 | $30.61 | $31.69 | $32.81 | +0.10% |
| May 31 | $30.39 | $31.71 | $33.08 | +0.15% |
| Jun 1 | $30.21 | $31.72 | $33.32 | +0.21% |
| Jun 2 | $30.05 | $31.74 | $33.53 | +0.26% |
| Jun 3 | $29.91 | $31.76 | $33.72 | +0.31% |
| Jun 4 | $29.78 | $31.77 | $33.90 | +0.36% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $29.78 | $31.77 | $33.90 | +0.36% |
| Week 2 | $29.09 | $31.89 | $34.95 | +0.72% |
| Week 3 | $28.60 | $32.00 | $35.81 | +1.08% |
| Week 4 | $28.21 | $32.12 | $36.57 | +1.45% |
| Week 5 | $27.88 | $32.23 | $37.26 | +1.81% |
| Week 6 | $27.60 | $32.35 | $37.92 | +2.18% |
| Week 7 | $27.35 | $32.47 | $38.54 | +2.54% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Its lead drug VK2809 is an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy.
The company was incorporated in 2012 and is headquartered in San Diego, California.
VKTX is a healthcare stock currently priced at $30.89 per share, with a market cap of $3.59B. It ranks 1592 in market capitalization, placing it among smaller-cap equities within the broader market.
The price outlook from the provided forecasts suggests bullish potential over the horizon, with the average price rising from $30.89 in 2026 to $49.41 in 2030, and then to $207.66 in 2050. The forecast also shows a progression in ROI, from 0% in 2026 to 60% in 2030 and up to 572.3% by 2050.
Year-by-year averages project ongoing upside, with 2027 at $41.26, 2028 at $46.03, 2029 at $47.58, 2031 at $55.26, 2032 at $57.42, 2033 at $69.19, 2034 at $81.56, and 2035 at $79.54; by 2040 the average is $120.14 and by 2050 it is $207.66.
Overall, the outlook points to meaningful upside over the long term, though these figures are estimates and not guarantees of future performance.
A major floor 21.9% below — a decisive break under it would weaken the trend.
The nearest floor, 10.3% below — buyers have tended to step in here.
The nearest ceiling, 12.2% above — a clean break opens room to run.
A major ceiling 23.2% above — clearing it would confirm fresh momentum.
Key VKTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of VKTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $30.69 | Buy | $30.85 | Buy |
| MA 10 | $30.42 | Buy | $30.73 | Buy |
| MA 20 | $30.90 | Buy | $31.14 | Buy |
| MA 50 | $32.60 | Sell | $32.03 | Sell |
| MA 100 | $32.28 | Sell | $32.47 | Sell |
| MA 200 | $32.55 | Sell | $32.95 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.19 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 62.73 | Neutral |
| Williams %R (14) | -1.81 | Info |
| MACD (12,26,9) | 0.14 | Buy |
| ROC (12) | 1.05 | Buy |
| Bollinger %B (20,2) | 0.68 | Neutral |
| Stochastic %K (14) | 98.19 | Sell |
| TRIX (15) | -0.36 | Sell |
| Awesome (5,34) | -1.61 | Sell |
| Ultimate (7,14,28) | 55.08 | Neutral |
| Momentum (10) | 0.34 | Buy |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 31.38 | Buy |
| ADX (14) | 13.62 | Neutral |
| ATR (14) | 0.71 | Info |
The 30-day technical picture shows neutral near-term dynamics. Market sentiment is NEUTRAL, with RSI14 at 50, indicating balanced momentum around the midpoint.
The stock’s price remains near key averages, with the 50-day SMA at $32.78 and the 200-day SMA at $32.61, providing a rough baseline for near-term trend relative to the current price.
Support is positioned at $28.40 and resistance at $35.53, framing a defined trading range. The 30-day price range spans from $26.14 to $36.51, illustrating modest volatility in a month-long window.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $26.29 | $31.66 | $46.88 | 0% | Neutral | |
| $33.65 | $42.01 | $55.36 | +33% | Bullish | |
| $36.88 | $47.17 | $64.22 | +49% | Bullish | |
| $37.47 | $48.89 | $68.30 | +54% | Bullish | |
| $38.10 | $50.61 | $72.26 | +60% | Bullish | |
| $42.22 | $57.00 | $82.96 | +80% | Bullish | |
| $43.36 | $59.44 | $88.02 | +88% | Bullish | |
| $50.97 | $70.85 | $106.59 | +124% | Bullish | |
| $59.41 | $83.72 | $127.78 | +164% | Bullish | |
| $57.73 | $82.40 | $127.47 | +160% | Bullish | |
| $81.99 | $124.02 | $203.07 | +292% | Bullish | |
| $129.29 | $215.88 | $384.21 | +582% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $26.29 | $31.66 | $37.06 | +0.00% |
| June 2026 | $27.22 | $31.90 | $38.21 | +0.75% |
| July 2026 | $28.10 | $33.18 | $40.23 | +4.00% |
| August 2026 | $28.26 | $33.57 | $41.08 | +1.18% |
| September 2026 | $28.25 | $33.72 | $41.58 | +0.45% |
| October 2026 | $29.49 | $35.35 | $43.90 | +4.84% |
| November 2026 | $30.75 | $37.01 | $46.24 | +4.69% |
| December 2026 | $30.88 | $37.31 | $46.88 | +0.81% |
Click any year to see its month-by-month VKTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, VKTX could reach as high as $46.88, with a base case around $31.66 and support toward $26.29 — roughly 0% from $31.66. Price action looks broadly range-bound.
Expect VKTX to range from $33.65 to $55.36 through 2027. The $42.01 average target implies a +33% move from current prices. That is up +33% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The VKTX price prediction for 2028 points to an average of $47.17 (low $36.88, high $64.22) — a potential gain of +49% on today's $31.66. Momentum favours further upside here.
In 2029, VKTX is projected to trade between $37.47 and $68.30, averaging $48.89 — a potential gain of +54% from today's $31.66. That is up +4% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Viking Therapeutics, Inc.'s 2030 outlook centres on $50.61, within a $38.10 to $72.26 range. That is up +4% on the projected 2029 average. That marks a +60% change versus current levels. Momentum favours further upside here.
By 2031, VKTX could reach as high as $82.96, with a base case around $57.00 and support toward $42.22 — roughly +80% from $31.66. Buyers look set to stay in control over this stretch.
Expect VKTX to range from $43.36 to $88.02 through 2032. The $59.44 average target implies a +88% move from current prices. That is up +4% on the projected 2031 average. Momentum favours further upside here.
The VKTX price prediction for 2033 points to an average of $70.85 (low $50.97, high $106.59) — a potential gain of +124% on today's $31.66. Buyers look set to stay in control over this stretch.
In 2034, VKTX is projected to trade between $59.41 and $127.78, averaging $83.72 — a potential gain of +164% from today's $31.66. That is up +18% on the projected 2033 average. Momentum favours further upside here.
Viking Therapeutics, Inc.'s 2035 outlook centres on $82.40, within a $57.73 to $127.47 range. That is -2% versus the projected 2034 average. That marks a +160% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, VKTX could reach as high as $203.07, with a base case around $124.02 and support toward $81.99 — roughly +292% from $31.66. Momentum favours further upside here.
Expect VKTX to range from $129.29 to $384.21 through 2050. The $215.88 average target implies a +582% move from current prices. That is up +74% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in VKTX today (≈ 31.585597 VKTX) could be worth
$6,818.8
+$5,818.8 (+582%) by 2050 · US Dollar
Based on the average projected VKTX price of $215.88 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in VKTXwould be worth at today's price.
$1,000 invested in VKTX on May 27, 2025 (≈ 36.791758 VKTX) would be worth
$1,164.83
+$164.83 (+16.5%) today · 1.16× · US Dollar
Based on a VKTX entry price of $27.18 vs. today's $31.66.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $29.44 | $1,075.41 | +7.5% |
| 1 month ago | $32.99 | $959.83 | -4.0% |
| 3 months ago | $32.97 | $960.27 | -4.0% |
| 6 months ago | $36.81 | $860.09 | -14.0% |
| 1 year ago | $27.18 | $1,164.83 | +16.5% |
| All time (5.0y) ago | $5.29 | $5,984.88 | +498.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our VKTX forecast.
Our base-case forecast reaches $63.00 around 2033.
Implied market cap at $63.00: $7.31B
The multi-year forecast shows meaningful upside across the horizon. The average price is projected to rise from $30.89 in 2026 to $49.41 in 2030, then to $120.14 in 2040 and $207.66 in 2050.
Projected ROI climbs from 0% in 2026 to 60% in 2030, 288.9% in 2040, and 572.3% in 2050, with bullish sentiment indicated for 2027 onward.
The forecast highlights continued positive momentum through 2037 and beyond, with annualized improvements in average price and corresponding ROI milestones through 2040 and 2050. These are estimates, not guarantees, and actual results may vary.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $49.41, with a minimum of $36.99 and a maximum of $71.02, and a projected ROI of 60%; sentiment is BULLISH.
Forecasts indicate bullish sentiment from 2027 onward, with the average price rising through 2027 ($41.26) and beyond, and ROIs climbing to 60% by 2030 and as high as 572.3% by 2050.
Yes. The forecast for 2033 lists a maximum of $104.92, suggesting a path where the price could exceed $100 in a best-case scenario.
Current price is $30.89 and market cap is $3.59B; the stock ranks 1592.
The 30-day range is from $26.14 to $36.51.
Viking Therapeutics, Inc. Community Discussion
0Share your Viking Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.